1 of 1
Longer-term data is in for CAR-T therapies from Novartis AG and Gilead Sciences, Inc. (via Gilead-owned Kite Pharma, Inc.) and the results show that certain patients who responded to Kymriah and Yescarta have maintained those responses 18 months on. Find out what this means to those in the CAR-T space in this interview with Pascal Touchon, Novartis’ Senior Vice President and Global Head, Cell & Gene Therapy, who spoke with Scrip during the last American Society of Hematology meeting in San Diego.
Note: Product cover images may vary from those shown
2 of 1